Clinical Trial Update: An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab

View source ↗

Summary

A completed observational Canadian study assessed changes in disease activity in adults with moderate-to-severe atopic dermatitis who inadequately responded to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Status: COMPLETED